retatrutide 2 months Effects of once-weekly subcutaneous on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials Retatrutide: The New Triple-Agonist Weight
Description
Clinical eligibility does not translate to real-world access
Hao Z, Townsend RL, Mumphrey MB, Morrison CD, Mnzberg H, Berthoud H-R
In TRIUMPH-4, nausea affected around 43% of participants on 12 mg, vomiting 21%, and diarrhoea 33%
If side effects resolve but you notice no benefits by month three, the product may not be right for your biology
It estimated that a $150 monthly cap could unlock access for up to 15 million Americans when applied to orforglipron, its experimental weight-loss pill that succeeded in a late-stage trial
